- Home
- BRNS vs RFL Comparison
BRNS vs RFL Comparison
Compare BRNS & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- RFL
- Stock Information
- Founded
- BRNS 2016
- RFL 2017
- Country
- BRNS United Kingdom
- RFL United States
- Employees
- BRNS N/A
- RFL N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- RFL Real Estate
- Sector
- BRNS Health Care
- RFL Finance
- Exchange
- BRNS Nasdaq
- RFL Nasdaq
- Market Cap
- BRNS 36.0M
- RFL 48.4M
- IPO Year
- BRNS 2021
- RFL N/A
- Fundamental
- Price
- BRNS $1.00
- RFL $1.84
- Analyst Decision
- BRNS Strong Buy
- RFL
- Analyst Count
- BRNS 1
- RFL 0
- Target Price
- BRNS $3.00
- RFL N/A
- AVG Volume (30 Days)
- BRNS 11.6K
- RFL 465.0K
- Earning Date
- BRNS 08-07-2025
- RFL 06-11-2025
- Dividend Yield
- BRNS N/A
- RFL N/A
- EPS Growth
- BRNS N/A
- RFL N/A
- EPS
- BRNS N/A
- RFL N/A
- Revenue
- BRNS $14,969,000.00
- RFL $732,000.00
- Revenue This Year
- BRNS N/A
- RFL N/A
- Revenue Next Year
- BRNS N/A
- RFL N/A
- P/E Ratio
- BRNS N/A
- RFL N/A
- Revenue Growth
- BRNS 4381.74
- RFL 35.56
- 52 Week Low
- BRNS $0.64
- RFL $1.27
- 52 Week High
- BRNS $1.58
- RFL $3.19
- Technical
- Relative Strength Index (RSI)
- BRNS 53.30
- RFL 52.36
- Support Level
- BRNS $0.90
- RFL $1.56
- Resistance Level
- BRNS $0.94
- RFL $2.04
- Average True Range (ATR)
- BRNS 0.05
- RFL 0.15
- MACD
- BRNS 0.00
- RFL -0.01
- Stochastic Oscillator
- BRNS 96.80
- RFL 52.56
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About RFL Rafael Holdings Inc. Class B
Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.